1Katz PO. Anderson C, Khoury R, et al. Gastro- oesophageal reflex associated with nocturnal gastrie acid breakthrough on proton punp inhibitors[J]. Aliment Pharmacol Ther 1998, 12:1231 - 1234.
2Williams MP, Sercombe J, Hamilton MI, et al. Aplacebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric and plasma gastrin concentrations in young healthy male subjects [J]. Aliment Pharmacol Ther 1998,12:1079-1089.
3Yasuda S, Horai Y, Tomono Y, et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton punp inhibitor, and omeprazole in relation to S - mephenytoin 4i - hydroxylation staus [J]. Clinic Pharmacol Ther 1995, 9:363 -378.
4Sohn D-R,Kwon J-T, Kim H-K, et al. Metabolic disposition of lansoprazole in relation to the S- mephnytoin 4i-hydroxylation phenotype status[J]. Clinic Pharmacol Ther 1997,61:574 - 582.
5Tanaka M, Ohkubo T, Otani K, et al. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S -mephenytoin 4' - hydroxylation phenotype and genotype[J].Clinic Pharmacol Ther 1997, 62:619-628.
6M. L. Cloud,N. Enas,T. J. Humphries,S. Bassion,The Rabeprazole Study Group. Rabeprazole in Treatment of Acid Peptic Diseases (Results of Three Placebo-Controlled Dose-Response Clinical Trials in Duodenal Ulcer, Gastric Ulcer, and Gastroesophageal Reflux Disease (GERD))[J] 1998,Digestive Diseases and Sciences(5):993～1000
